{"entity":{"type":"insider","cik":"0001789617","url":"/insider/0001789617","json_url":"/insider/0001789617.json","name":"Heerma Peter","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":24,"first":"2020-10-05","last":"2026-05-06","span_basis":"filed_date"},"name_variants":[{"name":"Heerma Peter","source":"filing","n_filings":24,"first_seen":"2020-10-05","last_seen":"2026-05-06"}],"transactions":[{"id":6224780,"accession":"0001789617-26-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001789617-26-000003","line_url":"/filing/0001789617-26-000003#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2174.0,"shares_display":"2,174","price_per_share":46.65,"price_display":"46.65","price_state":"stated","total_value":101417.1,"total_display":"101,417.10","total_whole":"101,417","shares_owned_after":140684.0,"shares_owned_after_display":"140,684","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider"},{"id":5989676,"accession":"0001789617-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001789617-26-000002","line_url":"/filing/0001789617-26-000002#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7215.0,"shares_display":"7,215","price_per_share":41.9288,"price_display":"41.93","price_state":"stated","total_value":302516.292,"total_display":"302,516.29","total_whole":"302,516","shares_owned_after":138608.0,"shares_owned_after_display":"138,608","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-15","scope":"insider"},{"id":5852000,"accession":"0001789617-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001789617-26-000001","line_url":"/filing/0001789617-26-000001#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7310.0,"shares_display":"7,310","price_per_share":32.12,"price_display":"32.12","price_state":"stated","total_value":234797.2,"total_display":"234,797.20","total_whole":"234,797","shares_owned_after":131823.0,"shares_owned_after_display":"131,823","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":5060586,"accession":"0001789617-25-000009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001789617-25-000009","line_url":"/filing/0001789617-25-000009#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4980.0,"shares_display":"4,980","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":199200.0,"total_display":"199,200.00","total_whole":"199,200","shares_owned_after":113013.0,"shares_owned_after_display":"113,013","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-24","filed_date":"2025-12-29","scope":"insider"},{"id":4933125,"accession":"0001789617-25-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001789617-25-000007","line_url":"/filing/0001789617-25-000007#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5591.0,"shares_display":"5,591","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":195685.0,"total_display":"195,685.00","total_whole":"195,685","shares_owned_after":119071.0,"shares_owned_after_display":"119,071","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-31","filed_date":"2025-11-04","scope":"insider"},{"id":4778030,"accession":"0001789617-25-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001789617-25-000006","line_url":"/filing/0001789617-25-000006#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2662.0,"shares_display":"2,662","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":79860.0,"total_display":"79,860.00","total_whole":"79,860","shares_owned_after":124662.0,"shares_owned_after_display":"124,662","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-30","scope":"insider"},{"id":4050979,"accession":"0001415889-25-012057","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012057","line_url":"/filing/0001415889-25-012057#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1771.0,"shares_display":"1,771","price_per_share":21.05,"price_display":"21.05","price_state":"stated","total_value":37279.55,"total_display":"37,279.55","total_whole":"37,280","shares_owned_after":128215.0,"shares_owned_after_display":"128,215","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-05","filed_date":"2025-05-05","scope":"insider"},{"id":4805226,"accession":"0001415889-25-003821","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-003821","line_url":"/filing/0001415889-25-003821#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2568.0,"shares_display":"2,568","price_per_share":23.5302,"price_display":"23.53","price_state":"stated","total_value":60425.5536,"total_display":"60,425.55","total_whole":"60,426","shares_owned_after":125066.0,"shares_owned_after_display":"125,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-12","filed_date":"2025-02-12","scope":"insider"},{"id":4805222,"accession":"0001415889-25-003821","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003821","line_url":"/filing/0001415889-25-003821#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3074.0,"shares_display":"3,074","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":76850.0,"total_display":"76,850.00","total_whole":"76,850","shares_owned_after":127634.0,"shares_owned_after_display":"127,634","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-11","filed_date":"2025-02-12","scope":"insider"},{"id":4805104,"accession":"0001415889-25-003063","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003063","line_url":"/filing/0001415889-25-003063#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5166.0,"shares_display":"5,166","price_per_share":20.12,"price_display":"20.12","price_state":"stated","total_value":103939.92,"total_display":"103,939.92","total_whole":"103,940","shares_owned_after":122708.0,"shares_owned_after_display":"122,708","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":4317913,"accession":"0001415889-25-002001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-002001","line_url":"/filing/0001415889-25-002001#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1584.0,"shares_display":"1,584","price_per_share":18.9408,"price_display":"18.94","price_state":"stated","total_value":30002.2272,"total_display":"30,002.23","total_whole":"30,002","shares_owned_after":106374.0,"shares_owned_after_display":"106,374","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":2564814,"accession":"0001415889-24-023092","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023092","line_url":"/filing/0001415889-24-023092#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2191.0,"shares_display":"2,191","price_per_share":11.52,"price_display":"11.52","price_state":"stated","total_value":25240.32,"total_display":"25,240.32","total_whole":"25,240","shares_owned_after":107958.0,"shares_owned_after_display":"107,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-09","scope":"insider"},{"id":2483682,"accession":"0001415889-24-002282","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002282","line_url":"/filing/0001415889-24-002282#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4195.0,"shares_display":"4,195","price_per_share":8.5313,"price_display":"8.53","price_state":"stated","total_value":35788.8035,"total_display":"35,788.80","total_whole":"35,789","shares_owned_after":99503.0,"shares_owned_after_display":"99,503","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider"},{"id":2221323,"accession":"0001415889-24-001797","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-001797","line_url":"/filing/0001415889-24-001797#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1559.0,"shares_display":"1,559","price_per_share":9.0684,"price_display":"9.07","price_state":"stated","total_value":14137.6356,"total_display":"14,137.64","total_whole":"14,138","shares_owned_after":78698.0,"shares_owned_after_display":"78,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":8726983,"accession":"0001209191-23-051885","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-051885","line_url":"/filing/0001209191-23-051885#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3091.0,"shares_display":"3,091","price_per_share":8.2511,"price_display":"8.25","price_state":"stated","total_value":25504.1501,"total_display":"25,504.15","total_whole":"25,504","shares_owned_after":80257.0,"shares_owned_after_display":"80,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-03","filed_date":"2023-10-04","scope":"insider"},{"id":8542987,"accession":"0001209191-23-006425","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-006425","line_url":"/filing/0001209191-23-006425#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1779.0,"shares_display":"1,779","price_per_share":21.752,"price_display":"21.75","price_state":"stated","total_value":38696.808,"total_display":"38,696.81","total_whole":"38,697","shares_owned_after":82069.0,"shares_owned_after_display":"82,069","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider"},{"id":8651070,"accession":"0001209191-23-005031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005031","line_url":"/filing/0001209191-23-005031#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1550.0,"shares_display":"1,550","price_per_share":21.9044,"price_display":"21.90","price_state":"stated","total_value":33951.82,"total_display":"33,951.82","total_whole":"33,952","shares_owned_after":63598.0,"shares_owned_after_display":"63,598","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-24","filed_date":"2023-01-26","scope":"insider"},{"id":6353652,"accession":"0001209191-22-053018","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-053018","line_url":"/filing/0001209191-22-053018#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3042.0,"shares_display":"3,042","price_per_share":25.68,"price_display":"25.68","price_state":"stated","total_value":78118.56,"total_display":"78,118.56","total_whole":"78,119","shares_owned_after":65148.0,"shares_owned_after_display":"65,148","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-04","filed_date":"2022-10-06","scope":"insider"},{"id":6976828,"accession":"0001209191-22-006363","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-006363","line_url":"/filing/0001209191-22-006363#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1125.0,"shares_display":"1,125","price_per_share":27.4,"price_display":"27.40","price_state":"stated","total_value":30825.0,"total_display":"30,825.00","total_whole":"30,825","shares_owned_after":67297.0,"shares_owned_after_display":"67,297","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-02","scope":"insider"},{"id":6271963,"accession":"0001209191-22-005082","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-005082","line_url":"/filing/0001209191-22-005082#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1875.0,"shares_display":"1,875","price_per_share":24.98,"price_display":"24.98","price_state":"stated","total_value":46837.5,"total_display":"46,837.50","total_whole":"46,838","shares_owned_after":58582.0,"shares_owned_after_display":"58,582","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-24","filed_date":"2022-01-26","scope":"insider"},{"id":4540190,"accession":"0001209191-21-059353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-059353","line_url":"/filing/0001209191-21-059353#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3058.0,"shares_display":"3,058","price_per_share":24.7698,"price_display":"24.77","price_state":"stated","total_value":75746.0484,"total_display":"75,746.05","total_whole":"75,746","shares_owned_after":60457.0,"shares_owned_after_display":"60,457","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-04","filed_date":"2021-10-05","scope":"insider"},{"id":5201727,"accession":"0001209191-21-052085","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-052085","line_url":"/filing/0001209191-21-052085#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1407.0,"shares_display":"1,407","price_per_share":17.1187,"price_display":"17.12","price_state":"stated","total_value":24086.0109,"total_display":"24,086.01","total_whole":"24,086","shares_owned_after":63515.0,"shares_owned_after_display":"63,515","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-17","filed_date":"2021-08-17","scope":"insider"},{"id":4329330,"accession":"0001209191-21-008814","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-008814","line_url":"/filing/0001209191-21-008814#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1125.0,"shares_display":"1,125","price_per_share":31.58,"price_display":"31.58","price_state":"stated","total_value":35527.5,"total_display":"35,527.50","total_whole":"35,528","shares_owned_after":59344.0,"shares_owned_after_display":"59,344","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-09","scope":"insider"},{"id":4329326,"accession":"0001209191-21-008814","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-008814","line_url":"/filing/0001209191-21-008814#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1125.0,"shares_display":"1,125","price_per_share":31.41,"price_display":"31.41","price_state":"stated","total_value":35336.25,"total_display":"35,336.25","total_whole":"35,336","shares_owned_after":60469.0,"shares_owned_after_display":"60,469","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider"},{"id":4716086,"accession":"0001209191-21-007636","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-007636","line_url":"/filing/0001209191-21-007636#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":563.0,"shares_display":"563","price_per_share":28.91,"price_display":"28.91","price_state":"stated","total_value":16276.33,"total_display":"16,276.33","total_whole":"16,276","shares_owned_after":57094.0,"shares_owned_after_display":"57,094","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-03","scope":"insider"},{"id":4716076,"accession":"0001209191-21-007636","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-007636","line_url":"/filing/0001209191-21-007636#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":563.0,"shares_display":"563","price_per_share":30.75,"price_display":"30.75","price_state":"stated","total_value":17312.25,"total_display":"17,312.25","total_whole":"17,312","shares_owned_after":57657.0,"shares_owned_after_display":"57,657","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-03","scope":"insider"},{"id":2738312,"accession":"0001209191-20-053925","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-053925","line_url":"/filing/0001209191-20-053925#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2188.0,"shares_display":"2,188","price_per_share":19.35,"price_display":"19.35","price_state":"stated","total_value":42337.8,"total_display":"42,337.80","total_whole":"42,338","shares_owned_after":42329.0,"shares_owned_after_display":"42,329","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-05","filed_date":"2020-10-05","scope":"insider"},{"id":2738307,"accession":"0001209191-20-053925","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-053925","line_url":"/filing/0001209191-20-053925#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Retrophin, Inc.","issuer_ticker":"RTRX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001789617","owner_name":"Heerma Peter","owner_display_name":"Heerma Peter","owner_url":"/insider/0001789617","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2188.0,"shares_display":"2,188","price_per_share":18.9,"price_display":"18.90","price_state":"stated","total_value":41353.2,"total_display":"41,353.20","total_whole":"41,353","shares_owned_after":44517.0,"shares_owned_after_display":"44,517","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-02","filed_date":"2020-10-05","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":28,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Officer (CHIEF COMMERCIAL OFFICER)","n_filings":24,"first_seen":"2020-10-05","last_seen":"2026-05-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001789617","retrieved_at":"2026-08-24T13:22:00+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}